DGAP-News: Heidelberg Pharma AG / Key word(s): Alliance
05.06.2019 / 07:10
The issuer is solely responsible for the content of this announcement.
Heidelberg Pharma Receives Milestone Payment from Partner Telix
Ladenburg, Germany, 5 June 2019 – Heidelberg Pharma AG (FSE: WL6) announced today that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia, (Telix). After licensing the imaging, radiolabeled antibody TLX250-CDx (formerly REDECTANE(R)), Telix has set up a new and modernized production process for the antibody Girentuximab. As part of this process, one of the contractually defined milestones has now been reached and payment became due.
Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: “It is a significant step forward that Telix was able to improve the production process for the in-licensed antibody and adapt it to current requirements. An improved production process is important for the execution of the entire study program. We are delighted to support the successful further development of this program and, of course, are also delighted about the milestone payment we have received.”
About TLX250-CDx (formerly REDECTANE(R))
About Heidelberg Pharma
The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON(R) and REDECTANE(R). Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.
About Telix Pharmaceuticals
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
05.06.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Heidelberg Pharma AG|
|Schriesheimer Str. 101|
|Phone:||+49 (0)89 41 31 38 – 0|
|Fax:||+49 (0)89 41 31 38 – 99|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||819129|
|End of News||DGAP News Service|